GlassScriptPhysician profile
Farid Abushamat
NPI 1629574975
$32,885.89
in general payments reported to CMS, 2019-2025
18 companies · $16K in 2025
The $16K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.80 · 2022: $287 · 2023: $470 · 2024: $16K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $25K · Food and Beverage: $4,291 · Travel and Lodging: $3,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $25,000.00 |
| Food and Beverage | $4,291.46 |
| Travel and Lodging | $3,274.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $30,348.37 | 2021-2025 | General - Therapies, Overstitch Endoscopic Suturing System, Axios |
| Abbvie INC. | $509.72 | 2022-2025 | Linzess, Mavyret, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $457.22 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $456.43 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.84 | 2022-2025 | Xifaxan, Trulance |
| Conmed Corporation | $222.27 | 2022-2025 | Conmed Generators |
| Phathom Pharmaceuticals, INC. | $123.78 | 2025 | Voquezna |
| Madrigal Pharmaceuticals | $102.92 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $79.08 | 2025 | Dupixent |
| Merck Sharp & Dohme LLC | $78.51 | 2023-2024 | Dificid |
| Echosens North America, INC. | $66.81 | 2025 | Fibroscan |
| Genzyme Corporation | $29.53 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $26.44 | 2025 | Terlivaz |
| Aimmune Therapeutics, INC. | $26.44 | 2025 | Zenpep |
| Lilly USA, LLC | $25.54 | 2025 | Omvoh |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $24.92 | 2025 | Ibsrela |
| Alcresta Therapeutics, INC. | $21.07 | 2023 | Relizorb |
| Shield Therapeutics INC | $18.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farid Abushamat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.